| Document |
Document Title |
|
WO/2024/092316A1 |
An animal watering system is disclosed. The animal watering system comprises an activated water source and an animal watering station configured to receive activated water from the activated water source. The activated water source compr...
|
|
WO/2024/097871A1 |
The invention relates to antigenic polypeptides derived from a naturally occurring R. microplus protein, and nucleic acids encoding such polypeptides. The polypeptides elicit an immune response which, in turn, produces detrimental effect...
|
|
WO/2024/094235A1 |
Compounds based on benzoxaborole moiety with activity against parasitic amoeba of genus Naegleria can be used in treatment of diseases caused by such parasites. Activity of the compounds against Naegleria fowleri was proven by a phenotyp...
|
|
WO/2024/089248A1 |
The present invention relates to a recombinant activation-associated secreted protein (ASP) or fragment thereof, said ASP or fragment comprising an N-glycan comprising a core α1,3-fucose and/or a core α1,6-fucose (Fuc). The invention f...
|
|
WO/2024/092113A1 |
The present disclosure provides targeted management methods for reducing, preventing, or controlling a parasitic infection or infestation in a fish population. The methods can include providing a fish feed including a pest control agent,...
|
|
WO/2024/092124A1 |
The present disclosure provides a method for reducing, preventing, or controlling a non-copepod parasitic infection or infestation in a fish population. The method includes providing a fish feed including a neem extract rich in azadirach...
|
|
WO/2024/082638A1 |
Provided in the present invention is the use of dimetridazole in the preparation of a drug for treating feline diarrhea caused by Tritrichomonas foetus in cats, and also provided is a dimetridazole chewable tablet preparation.
|
|
WO/2024/084186A1 |
The presentation invention relates to compounds of formula (I) and pharmaceutical compositions thereof. The compounds may be used to treat an infection, such as a parasitic infection or a bacterial infection. In some embodiments, the com...
|
|
WO/2024/080330A1 |
The present invention provides a compound having an excellent control effect against harmful arthropods. A compound represented by formula (1) and an N oxide thereof have an excellent control effect against harmful arthropods. [In the fo...
|
|
WO/2024/079276A1 |
The present invention relates to a method for synthesising a photolytically degradable compound, the method comprising defining a biologically active compound which analogue is to be synthesised, wherein the biologically active compound ...
|
|
WO/2024/080354A1 |
The present invention provides a compound, or an N-oxide thereof, which has an excellent controlling effect with respect to harmful arthropods and which is represented by formula (I) (in the formula: Q denotes a group represented by form...
|
|
WO/2024/080355A1 |
The present invention provides a compound represented by formula (I) [wherein, Q represented by the formula below (wherein # represents a binding site with a sulfur atom, and ● represents a binding site with Het) represents, inter alia...
|
|
WO/2024/079245A1 |
The invention relates to methods of treating clostridium difficile by administering ridinilazole, and pharmaceutically acceptable derivatives, salts, hydrates, solvates, complexes, bioisosteres, metabolites or prodrugs thereof.
|
|
WO/2024/081969A1 |
Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liver-stage parasite development of a protozoan parasite, such as Plasmodium falciparum. Also described herein are compounds, formu...
|
|
WO/2024/074554A1 |
The present invention relates to compositions and methods for treating or preventing infections, in particular infections by intracellular parasites such as Cryptosporidium spp. The present invention also relates to compositions and meth...
|
|
WO/2024/071393A1 |
The present invention provides a compound having an excellent control effect on harmful arthropods. A compound represented by formula (I) [wherein the meaning of each symbol is as described in the description] or N-oxide thereof has an e...
|
|
WO/2024/071219A1 |
According to the present invention, a compound represented by formula (I) (wherein, Q (# denotes a bonding site with a sulfur atom, and ● denotes a bonding site with Het) represented in the formula denotes a group or the like represent...
|
|
WO/2024/064931A1 |
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of Plasmodium protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the pre...
|
|
WO/2024/060838A1 |
Provided is a praziquantel pill suitable for distribution by unmanned aerial vehicles, comprising: praziquantel, and a bait layer and a waterproof layer that sequentially encapsulate praziquantel from inside to outside. The waterproof la...
|
|
WO/2024/064934A1 |
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the prese...
|
|
WO/2024/061665A1 |
The invention relates to isoxazoline compounds of formula I wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for p...
|
|
WO/2024/063788A1 |
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the prese...
|
|
WO/2024/064826A1 |
Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen...
|
|
WO/2024/063789A1 |
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of malarial protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the prese...
|
|
WO/2024/064886A1 |
The present invention relates to a nucleic acid molecule for eliciting an antigen-specific CD8+ T-cell response in a subject comprising a coding sequence encoding a polypeptide comprising an N-terminal degron and an antigenic peptide and...
|
|
WO/2024/055758A1 |
The present invention relates to the technical field of biological medicines. Disclosed are a cyclic dinucleotide metal compound, and a preparation method therefor and a use thereof. The structural formula of the compound is [M(cyclic di...
|
|
WO/2024/059803A1 |
An oral animal feed and a method of preventing and/or controlling parasitic worms in an mammal in need thereof by orally administering to the mammal, for example a canine, a feed or a composition comprising an effective amount of an anth...
|
|
WO/2024/059333A1 |
This disclosure describes compounds of Formula I and Formula II, pharmaceutically acceptable salts or derivatives thereof, and pharmaceutical compositions thereof, useful in treating infections caused by parasitic protozoa, in particular...
|
|
WO/2024/059837A1 |
An oral animal feed and a method of preventing and/or controlling heartworms in a mammal in need thereof by orally administering to the mammal, for example a canine, a feed comprising an effective amount of a systemic anthelmintic that h...
|
|
WO/2024/054115A1 |
The disclosure relates to organosulfur compounds and compositions comprising same. In particular, the disclosure relates to Bis(4-fluorophenyl) disulfide, Bis(4- chlorophenyl) disulfide, Bis(4-chlorophenyl) thiosulfinate, Bis(4-fluorophe...
|
|
WO/2024/003331A9 |
The present invention relates, generally, to beta-lactones comprising a spiro-fused ring and one beta-lactone ring and derivatives thereof, in particular an unprecedented macrolide named spirolactone, and their use as antimicrobial agents.
|
|
WO/2024/047241A1 |
The present invention relates to compounds and compositions of Formula (I) for treating a fasciolosis in a mammal.
|
|
WO/2024/048778A1 |
The present invention relates to an aryltetrahydropyridine compound represented by formula (1) or a salt thereof. [In formula (1), Q represents Q-1, etc.; J represents J-1, etc.; G represents G-1, etc.; R1 represents a halo(C1-C6)alkyl, ...
|
|
WO/2024/042930A1 |
The purpose of the present invention is to provide a pharmaceutical composition and the like for treating or preventing inflammation caused by Acanthamoeba. Specifically provided are a pharmaceutical composition for treating or preventin...
|
|
WO/2023/073641A9 |
This invention provides for compounds of the formula: (I) wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and methods for the treatment, control and/or prevention of a parasitic infesta...
|
|
WO/2024/042112A1 |
The present invention provides antigen binding proteins such as antibodies targeting Plasmodium sporozoites, in particular Plasmodium circumsporozoite protein. The invention also provides nucleic acids that encode such antibodies. In add...
|
|
WO/2024/038860A1 |
An onium salt of a nitrogen-containing (hetero)aryl compound according to the present invention is represented by formula (I) (in the formula, Q1 represents a pyrazole ring or the like, G1 represents a nitrogen or carbon atom, X1 represe...
|
|
WO/2024/033281A1 |
The present invention relates to novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments as well as methods of their use and manufacture. Said compounds are particularly useful...
|
|
WO/2024/033280A1 |
The present invention relates to novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments as well as methods of their use and manufacture. Said compounds are particularly useful...
|
|
WO/2024/034948A1 |
Provided in the present invention are a composition and a method for preventing or treating scuticociliatosis in Paralichthys olivaceus, the composition containing micronized liquid sulfur as an active ingredient. The composition of the ...
|
|
WO/2024/034565A1 |
Provided is a compound represented by formula (I-1a) or the like, or a salt thereof. [In formula (I-1a), R1 represents a substituted or unsubstituted C1-6 alkyl group, a substituted or unsubstituted C2-6 alkenyl group, or the like; R2 re...
|
|
WO/2024/026301A1 |
The present disclosure relates to vaccines, therapeutic antibodies and methods of making such vaccines and antibodies. More specifically, the disclosure relates to methods of immunofocusing an immune response to a protein having both neu...
|
|
WO/2024/026359A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...
|
|
WO/2024/022910A1 |
The present invention relates to compounds of formula (I) wherein: X is O or S; Q is Qa or Qb as pesticides and insecticides. Preferred compounds are e.g. 1-[1-[2-(pyrimidin-4-yl)-1,2,4-triazol-3-yl]ethyl]-3-[2,4-di
chloro-5-phenyl]urea ...
|
|
WO/2024/020333A2 |
Disclosed is a class of kinase inhibitors. Related pharmaceutical compositions and methods of making and using the kinase inhibitors are also disclosed.
|
|
WO/2022/251585A9 |
Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Plasmodium parasitic antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administerin...
|
|
WO/2024/011294A1 |
The present disclosure relates to compounds that find application as therapeutics. In particular, the disclosure relates to compounds of Formula (I) or Formula (II) and their pharmaceutically acceptable salt, solvates, or stereoisomers t...
|
|
WO/2024/003428A1 |
The present invention relates to quinone-derived compounds with leishmanicidal activity and to the use of same in the pharmaceutical industry, specifically in the field of parasitic diseases. The invention relates specifically to a compo...
|
|
WO/2024/003223A1 |
The present invention relates to a fucosylated saccharide, or a composition comprising a fucosylated saccharide, for use in preventing and/or treating a parasite infection in a subject, preferably cryptosporidiosis.
|
|
WO/2024/005032A1 |
In the production of crops in agriculture, horticulture, etc., due to factors such as damages caused by harmful bugs and the like still being significant and the emergence of harmful bugs resistant to existing drugs, there has been a dem...
|
